Technology transfer / Localization · GCC · Announced 28 Oct 2025
Local Content and Government Procurement Authority → Tabuk Pharmaceuticals
Saudi Arabia's LCGPA signed localisation agreements with Tabuk Pharmaceuticals for the biologic adalimumab and the oncology drug nilotinib at the Global Health Exhibition 2025 in Riyadh.
Parties: Local Content and Government Procurement Authority (LCGPA) (Saudi Arabia) → Tabuk Pharmaceuticals (Saudi Arabia)
- Deal type
- Technology transfer / Localization
- Value
- Undisclosed
- Territory
- Saudi Arabia — local manufacturing and knowledge transfer
- Therapeutic area
- Multi-therapy
- Assets
- adalimumab; nilotinib
- Announced
- 28 Oct 2025
Our analysis
Why this matters
On 28 October 2025, at the Global Health Exhibition in Riyadh, Saudi Arabia's Local Content and Government Procurement Authority (LCGPA) signed five localisation agreements. Tabuk Pharmaceuticals signed two of them: one for adalimumab, a biologic for chronic inflammatory diseases, and one for nilotinib capsules, a cancer treatment. Boston Oncology also signed for adalimumab, and Sudair and a company named only as "Pharma" also signed for nilotinib.
No value was given for each agreement. The LCGPA expects the five agreements together to add more than SAR 1.2 billion to GDP and about 500 direct jobs. Single source: Al Watan.
The full analysis is free to read with a work email on this page.
Source: Al Watan (Saudi Arabia)